Oxford Nanopore Technologies plc
("Oxford Nanopore" or the "Company")
Oxford Nanopore announces commencement of legal action against MGI Australia Pty Ltd., in the Federal Court of Australia
Oxford Nanopore Technologies plc (LSE: ONT), the company delivering a new generation of molecular sensing technology based on nanopores, today announces that it has launched legal action against MGI Australia Pty Ltd. et al., for infringing four of the Company's Australian patents following the announcement of the launch of its "Cyclone SEQ WT-02" in Australia.
Oxford Nanopore's decision to commence legal proceedings against MGI has been carefully considered and reflects the Company's responsibility to protect the intellectual property ("IP") that underpins its sensing platform, which is now widely used across Research and Applied sectors in Australia.
Throughout this process the primary focus will continue to be on customers, operations and partners. Protecting IP ensures that investments in new technology can be made available to customers and partners.
Oxford Nanopore continually innovates, to deliver high performance technologies to its customers. This innovation has generated substantial proprietary IP, which is a key foundation for long-term value creation. This IP is protected by patents granted in the U.S., Europe, Australia and other jurisdictions.
-ENDS-
For further information, please contact:
Oxford Nanopore Technologies plc
Investors: ir@nanoporetech.com
Media: media@nanoporetech.com
Teneo Australia (communications adviser to the Company)
Scott McFarlane: +61 493 119 547
Australian media: ONT-AUS@teneo.com
About Oxford Nanopore Technologies plc:
Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The Group has developed a new generation of nanopore-based sensing technology that is currently used for real-time, high-performance, accessible, and scalable analysis of DNA and RNA. The technology is used in more than 125 countries, to understand the biology of humans, plants, animals, bacteria, viruses and environments as well as to understand diseases such as cancer. Oxford Nanopore's technology also has the potential to provide broad, high impact, rapid insights in a number of areas including healthcare, food and agriculture.
For more information please visit: www.nanoporetech.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.